Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Druckformat: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v17.i1.40
pages 31-50

Therapeutic Targeting of the Epidermal Growth Factor Receptor in Human Cancer

Nathalie S. Dhomen
Ludwig Institute for Cancer Research, Melbourne, Australia
John Mariadason
Ludwig Institute for Cancer Research, Melbourne, Australia
Niall Tebbutt
Ludwig Institute for Cancer Research, Melbourne, Australia
Andrew M. Scott
Ludwig Institute for Cancer Research, Melbourne, Australia

ABSTRAKT

The epidermal growth factor receptor (EGFR; also referred to as HER1 or ERBB1), is a member of the type 1 receptor tyrosine kinase family known as the ERBB family. Comprising 4 members−ERBB1, ERBB2 (also known as HER2), ERBB3 (HER3), and ERBB4 (HER4)−these receptors play a principal role in allowing cells to integrate and respond correctly to diverse external stimuli, ranging from soluble endocrine and paracrine factors to signaling molecules on neighboring cells. The cell must interpret these extracellular signals to produce an appropriate developmental or proliferative response, and aberrant activation of the kinase activity of these receptors, particularly EGFR and ERBB2, is important in the development and progression of human cancer. Given its roles in signal transduction and development of the malignant phenotype, EGFR has emerged as a critical target for therapeutic development against various forms of cancer. This review focuses on the current therapeutic approaches directed against EGFR, the emerging challenges of EGFR therapy resistance, and how our increasing knowledge of EGFR biology is driving more targeted or alternative approaches to cancer therapies.


Articles with similar content:

Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 2
Vinod Prabhu, Venugopal Vinod Prabhu
Natural Products as Inhibitors of Epidermal Growth Factor Receptor
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth
The Tumor Microenvironment: A Target for Combination therapy of Breast Cancer
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 1-2
Ralph A. Reisfeld
Possible Molecular Targets of Bee Venom in the Treatment of Cancer: Application and Perspectives
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 3-4
Nada Orsolic
MicroRNAs in Bladder Cancer: Expression Profiles, Biological Functions, Regulation, and Clinical Implications
Critical Reviews™ in Eukaryotic Gene Expression, Vol.24, 2014, issue 1
Zhaoqi Shi, Mingxin Zhang, Junjun She, Qingxia Wei